Ullrich Bethe

Koeln, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Point prevalence assessments of five respiratory viruses in adults ≥ 50 years of age in Germany by multi-pathogen rapid antigen testing on June 1, 2024, and December 15, 2024.

Point prevalence assessments of five respiratory viruses in adults ≥ 50 years of age in Germany by multi-pathogen rapid antigen testing on June 1, 2024, and December 15, 2024.

Journal: Infection

Published: May 26, 2026

Immunogenicity, reactogenicity, and safety to assess booster vaccinations with BNT162b2 or double-dose mRNA-1273 in adults ≥75 years (EU-COVAT-1-AGED)-final report.

Immunogenicity, reactogenicity, and safety to assess booster vaccinations with BNT162b2 or double-dose mRNA-1273 in adults ≥75 years (EU-COVAT-1-AGED)-final report.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: December 23, 2025

Immunogenicity, reactogenicity and safety to assess booster vaccinations with BNT162b2 or double-dose mRNA-1273 in adults ≥75 years (EU-COVAT-1-AGED) - final report.

Immunogenicity, reactogenicity and safety to assess booster vaccinations with BNT162b2 or double-dose mRNA-1273 in adults ≥75 years (EU-COVAT-1-AGED) - final report.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: December 23, 2025

Self-testing for five respiratory viruses in adults ≥50 years of age in Germany for longitudinal monitoring of community-acquired acute respiratory infections.

Self-testing for five respiratory viruses in adults ≥50 years of age in Germany for longitudinal monitoring of community-acquired acute respiratory infections.

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Published: November 26, 2025

A supranational volunteer registry as a model for sustained vaccine research continuity and inclusive pandemic preparedness in Europe.

A supranational volunteer registry as a model for sustained vaccine research continuity and inclusive pandemic preparedness in Europe.

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Published: November 04, 2025

Self-testing for 5 respiratory viruses in adult VACCELERATE volunteers in Germany-a pilot study on multi-pathogen rapid antigen testing to monitor community-acquired acute respiratory infections.

Self-testing for 5 respiratory viruses in adult VACCELERATE volunteers in Germany-a pilot study on multi-pathogen rapid antigen testing to monitor community-acquired acute respiratory infections.

Journal: Frontiers in public health

Published: May 30, 2025

Revisiting diagnostics: early and accurate diagnosis of invasive fungal infections: a health economic view on investing in innovative diagnostics.

Revisiting diagnostics: early and accurate diagnosis of invasive fungal infections: a health economic view on investing in innovative diagnostics.

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Published: November 26, 2024

Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional Study.

Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional Study.

Journal: JMIR research protocols

Published: August 25, 2024

Innovative approaches for vaccine trials as a key component of pandemic preparedness - a white paper.

Innovative approaches for vaccine trials as a key component of pandemic preparedness - a white paper.

Journal: Infection

Published: May 21, 2024

Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B).

Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B).

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: March 27, 2024

Predicting the next pandemic: VACCELERATE ranking of the WorldHealth Organization's Blueprint forAction toPreventEpidemics.

Predicting the next pandemic: VACCELERATE ranking of the WorldHealth Organization's Blueprint forAction toPreventEpidemics.

Journal: Travel medicine and infectious disease

Published: August 01, 2023

Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1).

Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1).

Journal: Vaccine

Published: June 04, 2023

Showing 1-12 of 17

Last Updated: 09/26/2026